CA2906818A1 - Generation de bibliotheques d'adn acellulaire directement a partir du sang - Google Patents
Generation de bibliotheques d'adn acellulaire directement a partir du sangInfo
- Publication number
- CA2906818A1 CA2906818A1 CA2906818A CA2906818A CA2906818A1 CA 2906818 A1 CA2906818 A1 CA 2906818A1 CA 2906818 A CA2906818 A CA 2906818A CA 2906818 A CA2906818 A CA 2906818A CA 2906818 A1 CA2906818 A1 CA 2906818A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- dna
- sample
- sequencing
- free dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims description 200
- 239000008280 blood Substances 0.000 title claims description 200
- 238000000034 method Methods 0.000 claims abstract description 359
- 238000012163 sequencing technique Methods 0.000 claims abstract description 277
- 230000001605 fetal effect Effects 0.000 claims abstract description 91
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 81
- 238000012360 testing method Methods 0.000 claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 78
- 201000011510 cancer Diseases 0.000 claims abstract description 60
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 56
- 239000003599 detergent Substances 0.000 claims abstract description 40
- 239000007788 liquid Substances 0.000 claims abstract description 34
- 210000003754 fetus Anatomy 0.000 claims abstract description 31
- 238000007710 freezing Methods 0.000 claims abstract description 24
- 230000008014 freezing Effects 0.000 claims abstract description 24
- 230000027455 binding Effects 0.000 claims abstract description 20
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 12
- 239000011886 peripheral blood Substances 0.000 claims abstract description 12
- 238000010438 heat treatment Methods 0.000 claims abstract description 11
- 238000010257 thawing Methods 0.000 claims abstract description 8
- 239000000523 sample Substances 0.000 claims description 423
- 210000000349 chromosome Anatomy 0.000 claims description 246
- 210000002381 plasma Anatomy 0.000 claims description 218
- 150000007523 nucleic acids Chemical class 0.000 claims description 186
- 102000039446 nucleic acids Human genes 0.000 claims description 175
- 108020004707 nucleic acids Proteins 0.000 claims description 175
- 239000003550 marker Substances 0.000 claims description 107
- 230000008774 maternal effect Effects 0.000 claims description 99
- 208000036878 aneuploidy Diseases 0.000 claims description 98
- 230000008569 process Effects 0.000 claims description 96
- 231100001075 aneuploidy Toxicity 0.000 claims description 93
- 238000012217 deletion Methods 0.000 claims description 78
- 230000037430 deletion Effects 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 73
- 230000002759 chromosomal effect Effects 0.000 claims description 50
- 208000037280 Trisomy Diseases 0.000 claims description 41
- 239000000463 material Substances 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 40
- 238000005119 centrifugation Methods 0.000 claims description 36
- 210000000265 leukocyte Anatomy 0.000 claims description 33
- 239000011159 matrix material Substances 0.000 claims description 32
- 201000010374 Down Syndrome Diseases 0.000 claims description 31
- 230000036961 partial effect Effects 0.000 claims description 28
- 102000004506 Blood Proteins Human genes 0.000 claims description 27
- 108010017384 Blood Proteins Proteins 0.000 claims description 27
- 108091005804 Peptidases Proteins 0.000 claims description 27
- 239000004365 Protease Substances 0.000 claims description 26
- 206010044688 Trisomy 21 Diseases 0.000 claims description 26
- 230000003321 amplification Effects 0.000 claims description 26
- 239000012472 biological sample Substances 0.000 claims description 26
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 26
- 101710163270 Nuclease Proteins 0.000 claims description 25
- 239000013641 positive control Substances 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 239000000834 fixative Substances 0.000 claims description 21
- 210000004940 nucleus Anatomy 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 102000003960 Ligases Human genes 0.000 claims description 17
- 108090000364 Ligases Proteins 0.000 claims description 17
- 108010088751 Albumins Proteins 0.000 claims description 16
- 201000009928 Patau syndrome Diseases 0.000 claims description 16
- 206010044686 Trisomy 13 Diseases 0.000 claims description 16
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 claims description 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 15
- 206010053884 trisomy 18 Diseases 0.000 claims description 14
- 150000002500 ions Chemical class 0.000 claims description 13
- 201000006360 Edwards syndrome Diseases 0.000 claims description 12
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 12
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 12
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 claims description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000013507 mapping Methods 0.000 claims description 9
- 208000030454 monosomy Diseases 0.000 claims description 9
- 210000000601 blood cell Anatomy 0.000 claims description 8
- 238000005534 hematocrit Methods 0.000 claims description 8
- 230000001133 acceleration Effects 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 7
- 229940127219 anticoagulant drug Drugs 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 5
- 206010071547 Trisomy 9 Diseases 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- 206010053871 Trisomy 8 Diseases 0.000 claims description 3
- 206010044689 trisomy 22 Diseases 0.000 claims description 3
- 208000034298 trisomy chromosome 8 Diseases 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 abstract description 28
- 238000001514 detection method Methods 0.000 abstract description 15
- 206010008805 Chromosomal abnormalities Diseases 0.000 abstract description 14
- 230000009467 reduction Effects 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 359
- 102000053602 DNA Human genes 0.000 description 355
- 239000012634 fragment Substances 0.000 description 59
- 239000000203 mixture Substances 0.000 description 58
- 235000018102 proteins Nutrition 0.000 description 41
- 238000005516 engineering process Methods 0.000 description 35
- 241000282414 Homo sapiens Species 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 239000002773 nucleotide Substances 0.000 description 27
- 239000006228 supernatant Substances 0.000 description 24
- 108091092356 cellular DNA Proteins 0.000 description 23
- 102000040430 polynucleotide Human genes 0.000 description 23
- 108091033319 polynucleotide Proteins 0.000 description 23
- 239000002157 polynucleotide Substances 0.000 description 23
- 238000007481 next generation sequencing Methods 0.000 description 22
- 239000000306 component Substances 0.000 description 21
- 108010047956 Nucleosomes Proteins 0.000 description 19
- 230000031864 metaphase Effects 0.000 description 19
- 239000011324 bead Substances 0.000 description 18
- 239000013060 biological fluid Substances 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000002955 isolation Methods 0.000 description 17
- 230000001413 cellular effect Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000012530 fluid Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 12
- -1 formaldehyde) Chemical class 0.000 description 12
- 229920002477 rna polymer Polymers 0.000 description 12
- 102100027211 Albumin Human genes 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000011109 contamination Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 238000007399 DNA isolation Methods 0.000 description 10
- 238000012369 In process control Methods 0.000 description 10
- 208000026928 Turner syndrome Diseases 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 230000005945 translocation Effects 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 108010033040 Histones Proteins 0.000 description 9
- 108010020764 Transposases Proteins 0.000 description 9
- 102000008579 Transposases Human genes 0.000 description 9
- 230000005856 abnormality Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 210000001623 nucleosome Anatomy 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000004590 computer program Methods 0.000 description 8
- 210000004544 dc2 Anatomy 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 238000013467 fragmentation Methods 0.000 description 8
- 238000006062 fragmentation reaction Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 238000004190 ion pair chromatography Methods 0.000 description 8
- 238000002493 microarray Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 102000006947 Histones Human genes 0.000 description 7
- 210000004252 chorionic villi Anatomy 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 229960001484 edetic acid Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 201000000980 schizophrenia Diseases 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 208000031639 Chromosome Deletion Diseases 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 6
- 208000016679 Monosomy X Diseases 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 6
- 230000003196 chaotropic effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 230000017105 transposition Effects 0.000 description 6
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 5
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 102100034673 C-C motif chemokine 3-like 1 Human genes 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101000946370 Homo sapiens C-C motif chemokine 3-like 1 Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 210000001776 amniocyte Anatomy 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 230000003322 aneuploid effect Effects 0.000 description 5
- 208000029560 autism spectrum disease Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 210000003463 organelle Anatomy 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000012176 true single molecule sequencing Methods 0.000 description 5
- 206010003805 Autism Diseases 0.000 description 4
- 208000020706 Autistic disease Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 4
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 102100021947 Survival motor neuron protein Human genes 0.000 description 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000007672 fourth generation sequencing Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000003793 prenatal diagnosis Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 3
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 3
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 3
- 206010061764 Chromosomal deletion Diseases 0.000 description 3
- 208000036086 Chromosome Duplication Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 101001032462 Homo sapiens Glutathione S-transferase theta-1 Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010068052 Mosaicism Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 102100021582 Neurexin-1-beta Human genes 0.000 description 3
- 101000757182 Saccharomyces cerevisiae Glucoamylase S2 Proteins 0.000 description 3
- 108010012306 Tn5 transposase Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000011143 downstream manufacturing Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003426 interchromosomal effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 150000004713 phosphodiesters Chemical group 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000007841 sequencing by ligation Methods 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 210000001138 tear Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100026882 Alpha-synuclein Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100038326 Beta-defensin 4A Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000037051 Chromosomal Instability Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000006311 Cyclin D1 Human genes 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 238000006424 Flood reaction Methods 0.000 description 2
- 238000012424 Freeze-thaw process Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 102100036534 Glutathione S-transferase Mu 1 Human genes 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 2
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 2
- 101000866286 Homo sapiens Excitatory amino acid transporter 1 Proteins 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 101001071694 Homo sapiens Glutathione S-transferase Mu 1 Proteins 0.000 description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 2
- 101001108436 Homo sapiens Neurexin-1 Proteins 0.000 description 2
- 101001108433 Homo sapiens Neurexin-1-beta Proteins 0.000 description 2
- 101000996111 Homo sapiens Neuroligin-4, X-linked Proteins 0.000 description 2
- 101000822103 Homo sapiens Neuronal acetylcholine receptor subunit alpha-7 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101150013552 LDLR gene Proteins 0.000 description 2
- 108010033266 Lipoprotein(a) Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000010961 Monosomy 21 Diseases 0.000 description 2
- 102100034441 Neuroligin-4, X-linked Human genes 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 102100021511 Neuronal acetylcholine receptor subunit alpha-7 Human genes 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 2
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 2
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 2
- 102000012977 SLC1A3 Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 2
- 206010049644 Williams syndrome Diseases 0.000 description 2
- 208000006254 Wolf-Hirschhorn Syndrome Diseases 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000000285 glutaminergic effect Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000000661 isochromosome Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 101150091521 lpa gene Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000005257 nucleotidylation Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 210000003765 sex chromosome Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- IBAOFQIOOBQLHE-UHFFFAOYSA-N 2-amino-3,9-dihydropurin-9-ium-6-one;chloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N=CN2 IBAOFQIOOBQLHE-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 208000026817 47,XYY syndrome Diseases 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000037068 Abnormal Karyotype Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 108010012927 Apoprotein(a) Proteins 0.000 description 1
- 208000008037 Arthrogryposis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000025637 Autosomal monosomy Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100283975 Bos taurus GSTM1 gene Proteins 0.000 description 1
- 241000203231 Breda virus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000014392 Cat-eye syndrome Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 241001370750 Echinopsis oxygona Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 241000691979 Halcyon Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001032334 Homo sapiens Immunity-related GTPase family M protein Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000848721 Homo sapiens Rap guanine nucleotide exchange factor 4 Proteins 0.000 description 1
- 101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102100038249 Immunity-related GTPase family M protein Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000004706 Jacobsen Distal 11q Deletion Syndrome Diseases 0.000 description 1
- 208000029279 Jacobsen Syndrome Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 208000037699 Monosomy 18p Diseases 0.000 description 1
- 208000019209 Monosomy 22 Diseases 0.000 description 1
- 208000033180 Monosomy 22q13.3 Diseases 0.000 description 1
- 208000010610 Mosaic trisomy 8 Diseases 0.000 description 1
- 241001489398 Narcissus symptomless virus Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 101710203761 Neurexin-1 Proteins 0.000 description 1
- 229940122426 Nuclease inhibitor Drugs 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 101150084935 PTER gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100034591 Rap guanine nucleotide exchange factor 4 Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004523 Sulfate Adenylyltransferase Human genes 0.000 description 1
- 108010022348 Sulfate adenylyltransferase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101100388071 Thermococcus sp. (strain GE8) pol gene Proteins 0.000 description 1
- 102100030780 Transcriptional activator Myb Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010062757 Trisomy 15 Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 201000001305 Williams-Beuren syndrome Diseases 0.000 description 1
- 206010056894 XYY syndrome Diseases 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IRLPACMLTUPBCL-FCIPNVEPSA-N adenosine-5'-phosphosulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO[P@](O)(=O)OS(O)(=O)=O)[C@H](O)[C@H]1O IRLPACMLTUPBCL-FCIPNVEPSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000025150 arthrogryposis multiplex congenita Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000001870 benign paroxysmal positional vertigo Diseases 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000010261 blood fractionation Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000004664 chromosome 18p deletion syndrome Diseases 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 201000007850 distal arthrogryposis Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000036282 monosomy chromosome 8 Diseases 0.000 description 1
- 208000010684 mosaic trisomy 4 Diseases 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 108010009127 mu transposase Proteins 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 101150114277 mycb gene Proteins 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 208000014813 partial deletion of chromosome 18 Diseases 0.000 description 1
- 208000011383 partial deletion of the short arm of chromosome 8 Diseases 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 108010062513 snake venom phosphodiesterase I Proteins 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000015344 trisomy 17p Diseases 0.000 description 1
- 208000026485 trisomy X Diseases 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Abstract
La présente invention concerne des procédés et trousses pour la préparation de bibliothèque de séquençage pour détecter une anomalie chromosomique au moyen d'ADN acellulaire (cfDNA) sans nécessiter un isolement préalable de l'ADN acellulaire depuis une fraction liquide d'un échantillon pour essai. Selon certains modes de réalisation, le procédé comprend la réduction de liaison entre l'ADN acellulaire et des protéines nucléosomiques sans déroulement de l'ADN acellulaire depuis les protéines nucléosomiques. Selon certains modes de réalisation, la réduction de liaison comprend également la congélation et la décongélation de l'échantillon pour essai avant la réduction de la liaison entre l'ADN acellulaire et les protéines nucléosomiques. Selon certains modes de réalisation, l'échantillon pour essai est un échantillon de sang périphérique prélevé d'une femme enceinte comportant l'ADN acellulaire de la maman et du ftus, les procédés pouvant être utilisés pour détecter une anomalie chromosomique ftale tel qu'une variation du nombre de copies. Selon d'autres modes de réalisation, l'échantillon pour essai est un échantillon de sang périphérique prélevé d'un patient connu ou suspecté d'être atteint d'un cancer, les procédés pouvant être utilisés pour détecter des anomalies chromosomiques dans l'ADN acellulaire du patient. L'invention concerne également des trousses pour la détection de variation du nombre de copies du ftus au moyen des procédés selon la présente invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3156663A CA3156663A1 (fr) | 2013-03-15 | 2014-03-14 | Generation de bibliotheques d'adn acellulaire directement a partir du sang |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801126P | 2013-03-15 | 2013-03-15 | |
| US61/801,126 | 2013-03-15 | ||
| PCT/US2014/029739 WO2014145078A1 (fr) | 2013-03-15 | 2014-03-14 | Génération de bibliothèques d'adn acellulaire directement à partir du sang |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3156663A Division CA3156663A1 (fr) | 2013-03-15 | 2014-03-14 | Generation de bibliotheques d'adn acellulaire directement a partir du sang |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2906818A1 true CA2906818A1 (fr) | 2014-09-18 |
| CA2906818C CA2906818C (fr) | 2022-08-16 |
Family
ID=50489439
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3156663A Pending CA3156663A1 (fr) | 2013-03-15 | 2014-03-14 | Generation de bibliotheques d'adn acellulaire directement a partir du sang |
| CA2906818A Active CA2906818C (fr) | 2013-03-15 | 2014-03-14 | Generation de bibliotheques d'adn acellulaire directement a partir du sang |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3156663A Pending CA3156663A1 (fr) | 2013-03-15 | 2014-03-14 | Generation de bibliotheques d'adn acellulaire directement a partir du sang |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10017807B2 (fr) |
| EP (2) | EP3409791B1 (fr) |
| AU (2) | AU2014233373B2 (fr) |
| CA (2) | CA3156663A1 (fr) |
| WO (1) | WO2014145078A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111742058A (zh) * | 2018-02-21 | 2020-10-02 | 纽克莱克斯有限公司 | 用于确定从全血分离血浆的效率的方法和试剂盒 |
Families Citing this family (199)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| EP2854057B1 (fr) | 2010-05-18 | 2018-03-07 | Natera, Inc. | Procédés pour une classification de ploïdie prénatale non invasive |
| CA2824387C (fr) | 2011-02-09 | 2019-09-24 | Natera, Inc. | Procedes de classification de ploidie prenatale non invasive |
| US9892230B2 (en) | 2012-03-08 | 2018-02-13 | The Chinese University Of Hong Kong | Size-based analysis of fetal or tumor DNA fraction in plasma |
| US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10584381B2 (en) | 2012-08-14 | 2020-03-10 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
| US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| EP2885418A4 (fr) | 2012-08-14 | 2016-03-02 | 10X Genomics Inc | Compositions de microcapsule et procédés |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| EP4424826A3 (fr) | 2012-09-04 | 2024-11-27 | Guardant Health, Inc. | Systèmes et procédés de détection de mutations rares et de variation du nombre de copies |
| US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US10482994B2 (en) | 2012-10-04 | 2019-11-19 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP4293125A3 (fr) | 2012-12-10 | 2024-02-28 | Resolution Bioscience, Inc. | Procédés d'analyse génomique ciblée |
| WO2014093676A1 (fr) | 2012-12-14 | 2014-06-19 | 10X Technologies, Inc. | Procédés et systèmes pour le traitement de polynucléotides |
| US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| CA2900481A1 (fr) | 2013-02-08 | 2014-08-14 | 10X Genomics, Inc. | Generation de codes a barres de polynucleotides |
| EP3409791B1 (fr) | 2013-03-15 | 2021-06-30 | Verinata Health, Inc. | Génération de banques d'adn acellulaire provenant directement du sang |
| US10059989B2 (en) | 2013-05-23 | 2018-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Transposition of native chromatin for personal epigenomics |
| AU2014268377B2 (en) | 2013-05-24 | 2020-10-08 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10395758B2 (en) | 2013-08-30 | 2019-08-27 | 10X Genomics, Inc. | Sequencing methods |
| BR112016010095A2 (pt) | 2013-11-07 | 2017-09-12 | Univ Leland Stanford Junior | ácidos nucleicos de célula livre para a ánalise de microbioma humano e componentes do mesmos. |
| US11859246B2 (en) | 2013-12-11 | 2024-01-02 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| IL300974A (en) | 2013-12-11 | 2023-04-01 | Accuragen Holdings Ltd | Preparations and methods for the detection of rare sequence variants |
| US11286519B2 (en) | 2013-12-11 | 2022-03-29 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| US9824068B2 (en) | 2013-12-16 | 2017-11-21 | 10X Genomics, Inc. | Methods and apparatus for sorting data |
| EP3378952B1 (fr) | 2013-12-28 | 2020-02-05 | Guardant Health, Inc. | Procédés et systèmes de détection de variants génétiques |
| US9694361B2 (en) | 2014-04-10 | 2017-07-04 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
| AU2015249846B2 (en) | 2014-04-21 | 2021-07-22 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| US10975371B2 (en) * | 2014-04-29 | 2021-04-13 | Illumina, Inc. | Nucleic acid sequence analysis from single cells |
| US20180173845A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| US12312640B2 (en) | 2014-06-26 | 2025-05-27 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
| CN106536756A (zh) | 2014-06-26 | 2017-03-22 | 10X基因组学有限公司 | 核酸序列的分析 |
| EP3161160B1 (fr) | 2014-06-26 | 2021-10-13 | 10X Genomics, Inc. | Procédés d'analyse d'acides nucléiques provenant de cellules individuelles ou de populations de cellules |
| PT3543356T (pt) | 2014-07-18 | 2021-10-04 | Univ Hong Kong Chinese | Análise dos padrões de metilação de tecidos em mistura de adn |
| EP3175000B1 (fr) | 2014-07-30 | 2020-07-29 | Sequenom, Inc. | Méthodes et procédés d'évaluation non invasive de variations génétiques |
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| CN104293941B (zh) * | 2014-09-30 | 2017-01-11 | 天津华大基因科技有限公司 | 构建测序文库的方法及其应用 |
| CN104293940B (zh) * | 2014-09-30 | 2017-07-28 | 天津华大基因科技有限公司 | 构建测序文库的方法及其应用 |
| US11094398B2 (en) | 2014-10-10 | 2021-08-17 | Life Technologies Corporation | Methods for calculating corrected amplicon coverages |
| US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
| WO2016077409A1 (fr) * | 2014-11-12 | 2016-05-19 | Neogenomics Laboratories, Inc. | Détermination de la charge tumorale et d'une mutation bi-allélique chez les patients porteurs d'une mutation calr faisant appel au plasma sanguin périphérique |
| US9944993B2 (en) * | 2015-01-06 | 2018-04-17 | Haplox Biotechnology (Shenzhen) Co., Ltd. | Method for enrichment of circulating tumor DNA and reagent for enrichment of circulating tumor DNA |
| CN107427808B (zh) | 2015-01-12 | 2020-10-23 | 10X基因组学有限公司 | 用于制备核酸测序文库的方法和系统以及用其制备的文库 |
| US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
| CA2976303A1 (fr) | 2015-02-10 | 2016-08-18 | The Chinese University Of Hong Kong | Detection de mutations utilisees pour le depistage du cancer et l'analyse ftale |
| WO2016137973A1 (fr) | 2015-02-24 | 2016-09-01 | 10X Genomics Inc | Procédés et systèmes de traitement de cloisonnement |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| KR101967878B1 (ko) * | 2015-03-12 | 2019-04-11 | 재단법인 아산사회복지재단 | 순환 유리 핵산의 분리 방법 |
| KR20170138566A (ko) | 2015-04-29 | 2017-12-15 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 가닥 특이적 cDNA 라이브러리를 작제하기 위한 조성물 및 방법 |
| EP4428863A3 (fr) | 2015-05-11 | 2024-12-11 | Natera, Inc. | Procédés et compositions pour déterminer la ploïdie |
| CN107922971A (zh) * | 2015-05-18 | 2018-04-17 | 凯锐思公司 | 用于富集核酸群体的组合物和方法 |
| CN104894268B (zh) * | 2015-06-05 | 2018-02-09 | 上海美吉生物医药科技有限公司 | 定量样本中源自细胞凋亡的dna浓度的方法及其应用 |
| IL288622B2 (en) | 2015-07-23 | 2024-03-01 | Univ Hong Kong Chinese | Analysis of fragmentation patterns of cell-free dna |
| WO2017027835A1 (fr) * | 2015-08-12 | 2017-02-16 | Circulogene Theranostics, Llc | Procédé de préparation de molécules d'acide nucléique sans cellule par amplification in situ |
| HK1259101A1 (zh) | 2015-10-09 | 2019-11-22 | Accuragen Holdings Limited | 用於富集扩增产物的方法及组合物 |
| ES2856598T3 (es) * | 2015-11-11 | 2021-09-27 | Resolution Bioscience Inc | Construcción de alta eficiencia de bibliotecas de ADN |
| US11371094B2 (en) | 2015-11-19 | 2022-06-28 | 10X Genomics, Inc. | Systems and methods for nucleic acid processing using degenerate nucleotides |
| US20170145475A1 (en) * | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| WO2017096322A1 (fr) | 2015-12-03 | 2017-06-08 | Accuragen Holdings Limited | Méthodes et compositions pour former des produits de ligature |
| PT3882357T (pt) | 2015-12-04 | 2022-09-05 | 10X Genomics Inc | Métodos e composições para análise de ácidos nucleicos |
| WO2017106768A1 (fr) | 2015-12-17 | 2017-06-22 | Guardant Health, Inc. | Procédés de détermination du nombre de copies du gène tumoral par analyse d'adn acellulaire |
| US20170175182A1 (en) * | 2015-12-18 | 2017-06-22 | Agilent Technologies, Inc. | Transposase-mediated barcoding of fragmented dna |
| JP6735348B2 (ja) | 2016-02-11 | 2020-08-05 | １０エックス ジェノミクス， インコーポレイテッド | 全ゲノム配列データのデノボアセンブリのためのシステム、方法及び媒体 |
| EP4198146A3 (fr) | 2016-03-25 | 2023-08-23 | Karius, Inc. | Procédé utilisant des spike-ins d'acides nucléiques synthétiques |
| RU2760913C2 (ru) | 2016-04-15 | 2021-12-01 | Натера, Инк. | Способы выявления рака легкого |
| WO2017197343A2 (fr) | 2016-05-12 | 2017-11-16 | 10X Genomics, Inc. | Filtres microfluidiques sur puce |
| WO2017197338A1 (fr) | 2016-05-13 | 2017-11-16 | 10X Genomics, Inc. | Systèmes microfluidiques et procédés d'utilisation |
| EP3458586B1 (fr) | 2016-05-16 | 2022-12-28 | Accuragen Holdings Limited | Procédé de séquençage amélioré par identification de brin |
| US10240196B2 (en) * | 2016-05-27 | 2019-03-26 | Agilent Technologies, Inc. | Transposase-random priming DNA sample preparation |
| WO2017214557A1 (fr) | 2016-06-10 | 2017-12-14 | Counsyl, Inc. | Adaptateurs de séquençage d'acide nucléique et leurs utilisations |
| WO2018013837A1 (fr) | 2016-07-15 | 2018-01-18 | The Regents Of The University Of California | Procédés de production de bibliothèques d'acides nucléiques |
| ES2873723T3 (es) * | 2016-07-22 | 2021-11-03 | Univ Oregon Health & Science | Colecciones de genoma completo de células individuales y métodos de indexación combinatoria para prepararlas |
| WO2018035170A1 (fr) | 2016-08-15 | 2018-02-22 | Accuragen Holdings Limited | Compositions et procédés permettant de détecter des variants de séquences rares |
| WO2018039463A1 (fr) | 2016-08-25 | 2018-03-01 | Resolution Bioscience, Inc. | Procédés de détection de changements de copie génomique dans des échantillons d'adn |
| WO2018064486A1 (fr) | 2016-09-29 | 2018-04-05 | Counsyl, Inc. | Dépistage prénatal non invasif utilisant une optimisation de profondeur itérative dynamique |
| US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| EP3529374B1 (fr) * | 2016-10-21 | 2024-04-03 | Exosome Diagnostics, Inc. | Sequencage et analyse d'acides nucleic exosomales |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| EP4345168A3 (fr) * | 2016-11-17 | 2024-07-31 | LGC Clinical Diagnostics, Inc. | Procédés de préparation de matériau de référence d'adn et témoins |
| CA3039685A1 (fr) | 2016-11-30 | 2018-06-07 | The Chinese University Of Hong Kong | Analyse d'adn acellulaire dans l'urine et d'autres echantillons |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| IL319365A (en) | 2017-01-24 | 2025-05-01 | Sequenom Inc | Methods and processes for assessing genetic variations |
| DK3574108T3 (da) | 2017-01-25 | 2024-09-16 | Univ Hong Kong Chinese | Diagnostisk anvendelse ved brug af nukleinsyrefragment |
| CN117512066A (zh) | 2017-01-30 | 2024-02-06 | 10X基因组学有限公司 | 用于基于微滴的单细胞条形编码的方法和系统 |
| US12264411B2 (en) | 2017-01-30 | 2025-04-01 | 10X Genomics, Inc. | Methods and systems for analysis |
| WO2018144216A1 (fr) | 2017-01-31 | 2018-08-09 | Counsyl, Inc. | Procédés et compositions pour l'enrichissement de polynucléotides cibles |
| US10752946B2 (en) * | 2017-01-31 | 2020-08-25 | Myriad Women's Health, Inc. | Methods and compositions for enrichment of target polynucleotides |
| US10995333B2 (en) | 2017-02-06 | 2021-05-04 | 10X Genomics, Inc. | Systems and methods for nucleic acid preparation |
| US10894976B2 (en) * | 2017-02-21 | 2021-01-19 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
| WO2018160907A1 (fr) * | 2017-03-03 | 2018-09-07 | Counsyl, Inc. | Extraction d'acides nucléiques pour une variabilité réduite du nombre de sondes |
| PT3596233T (pt) | 2017-03-17 | 2022-08-22 | Sequenom Inc | Métodos e processos para avaliação de mosaicismo genético |
| EP3602359A4 (fr) | 2017-03-24 | 2021-01-06 | Myriad Women's Health, Inc. | Appelant de variante de nombre de copies |
| CA3059370C (fr) | 2017-04-12 | 2022-05-10 | Karius, Inc. | Methodes d'analyse simultanee de l'adn et de l'arn dans des echantillonsmelanges |
| ES3035812T3 (en) * | 2017-04-17 | 2025-09-09 | Genefirst Ltd | Methods and kits for preparing nucleic acid libraries |
| EP3612644B1 (fr) * | 2017-04-18 | 2021-12-15 | Agilent Technologies Belgium NV | Utilisation de séquences hors cible pour l'analyse d'adn |
| US10858691B2 (en) * | 2017-04-18 | 2020-12-08 | Covaris, Inc. | Differential shearing of nucleic acids |
| EP3445876B1 (fr) | 2017-05-26 | 2023-07-05 | 10X Genomics, Inc. | Analyse de la chromatine accessible par une transposase d'une cellule unique |
| US20180340169A1 (en) | 2017-05-26 | 2018-11-29 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
| US11869630B2 (en) * | 2017-07-18 | 2024-01-09 | Congenica Ltd. | Screening system and method for determining a presence and an assessment score of cell-free DNA fragments |
| CN111051536A (zh) | 2017-07-26 | 2020-04-21 | 香港中文大学 | 利用不含细胞的病毒核酸改善癌症筛选 |
| US10837047B2 (en) | 2017-10-04 | 2020-11-17 | 10X Genomics, Inc. | Compositions, methods, and systems for bead formation using improved polymers |
| JP7293244B2 (ja) | 2017-10-19 | 2023-06-19 | ストレック， インコーポレイテッド | 溶血、凝固調節および細胞外小胞の安定化のための組成物 |
| WO2019084043A1 (fr) | 2017-10-26 | 2019-05-02 | 10X Genomics, Inc. | Méthodes et systèmes de préparation d'acide nucléique et d'analyse de chromatine |
| WO2019084245A1 (fr) * | 2017-10-27 | 2019-05-02 | Myriad Women's Health, Inc. | Méthodes et compositions utilisables pour préparer des bibliothèques d'acides nucléiques |
| JP2021500883A (ja) * | 2017-10-27 | 2021-01-14 | ジュノ ダイアグノスティックス，インク． | 超微量リキッドバイオプシーのためのデバイス、システム、および方法 |
| EP3700672B1 (fr) | 2017-10-27 | 2022-12-28 | 10X Genomics, Inc. | Procédés de préparation et d'analyse d'échantillons |
| EP3625361A1 (fr) | 2017-11-15 | 2020-03-25 | 10X Genomics, Inc. | Perles de gel fonctionnalisées |
| US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
| CN111386362B (zh) * | 2017-11-27 | 2024-11-12 | 深圳华大生命科学研究院 | 一种体液游离dna的文库构建方法及其应用 |
| WO2019108851A1 (fr) | 2017-11-30 | 2019-06-06 | 10X Genomics, Inc. | Systèmes et procédés de préparation et d'analyse d'acides nucléiques |
| CN111699388B (zh) | 2017-12-12 | 2024-08-02 | 10X基因组学有限公司 | 用于单细胞处理的系统和方法 |
| WO2019118926A1 (fr) | 2017-12-14 | 2019-06-20 | Tai Diagnostics, Inc. | Évaluation de la compatibilité d'une greffe pour la transplantation |
| WO2019126789A1 (fr) | 2017-12-22 | 2019-06-27 | 10X Genomics, Inc. | Systèmes et procédés de traitement de molécules d'acide nucléique provenant d'une ou de plusieurs cellules |
| CA3087001A1 (fr) | 2018-01-12 | 2019-07-18 | Claret Bioscience, Llc | Procedes et compositions d'analyse d'acide nucleique |
| WO2019152108A1 (fr) | 2018-02-05 | 2019-08-08 | The Board Of Trustees Of The Leland Stanford Junior University | Systèmes et procédés pour des mesures multiplexées dans des cellules uniques et d'ensemble |
| KR102036609B1 (ko) * | 2018-02-12 | 2019-10-28 | 바이오코아 주식회사 | 디지털 pcr을 이용한 산전진단 방법 |
| EP3752832A1 (fr) | 2018-02-12 | 2020-12-23 | 10X Genomics, Inc. | Procédés de caractérisation d'analytes multiples à partir de cellules individuelles ou de populations cellulaires |
| US12398389B2 (en) | 2018-02-15 | 2025-08-26 | Natera, Inc. | Methods for isolating nucleic acids with size selection |
| US11639928B2 (en) | 2018-02-22 | 2023-05-02 | 10X Genomics, Inc. | Methods and systems for characterizing analytes from individual cells or cell populations |
| WO2019169028A1 (fr) | 2018-02-28 | 2019-09-06 | 10X Genomics, Inc. | Séquençage de transcriptomes par ligation aléatoire |
| GB201819134D0 (en) * | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Improvements in variant detection |
| JP2021514663A (ja) | 2018-03-08 | 2021-06-17 | セント・ジョーンズ・ユニバーシティＳｔ． Ｊｏｈｎｓ Ｕｎｉｖｅｒｓｉｔｙ | 循環性血清無細胞ｄｎａバイオマーカー及び方法 |
| CA3082601A1 (fr) | 2018-03-16 | 2019-09-19 | Karius, Inc. | Serie d'echantillons pour differencier des acides nucleiques cibles d'acides nucleiques contaminants |
| US11203782B2 (en) | 2018-03-29 | 2021-12-21 | Accuragen Holdings Limited | Compositions and methods comprising asymmetric barcoding |
| CA3095030A1 (fr) | 2018-03-30 | 2019-10-03 | Juno Diagnostics, Inc. | Procedes, dispositifs et systemes bases sur l'apprentissage profond pour le depistage antenatal |
| KR102383799B1 (ko) * | 2018-04-02 | 2022-04-05 | 일루미나, 인코포레이티드 | 서열-기반의 유전 검사용 대조군을 제조하기 위한 조성물 및 방법 |
| GB2587939B (en) | 2018-04-02 | 2023-06-14 | Grail Llc | Methylation markers and targeted methylation probe panels |
| CN112262218B (zh) | 2018-04-06 | 2024-11-08 | 10X基因组学有限公司 | 用于单细胞处理中的质量控制的系统和方法 |
| EP3781714B1 (fr) | 2018-04-14 | 2026-01-07 | Natera, Inc. | Procédés de détection et de surveillance du cancer au moyen d'une détection personnalisée d'adn tumoral circulant |
| WO2019217758A1 (fr) | 2018-05-10 | 2019-11-14 | 10X Genomics, Inc. | Procédés et systèmes de génération de banque moléculaire |
| AU2019270185A1 (en) | 2018-05-17 | 2020-01-16 | Illumina, Inc. | High-throughput single-cell sequencing with reduced amplification bias |
| EP3802864A1 (fr) | 2018-06-06 | 2021-04-14 | The Regents Of The University Of California | Procédés de production de bibliothèques d'acides nucléiques et compositions et kits pour leur mise en oeuvre |
| US11932899B2 (en) | 2018-06-07 | 2024-03-19 | 10X Genomics, Inc. | Methods and systems for characterizing nucleic acid molecules |
| WO2019241290A1 (fr) | 2018-06-12 | 2019-12-19 | Accuragen Holdings Limited | Méthodes et compositions pour former des produits de ligature |
| US11703427B2 (en) | 2018-06-25 | 2023-07-18 | 10X Genomics, Inc. | Methods and systems for cell and bead processing |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| US12188014B1 (en) | 2018-07-25 | 2025-01-07 | 10X Genomics, Inc. | Compositions and methods for nucleic acid processing using blocking agents |
| US20200032335A1 (en) | 2018-07-27 | 2020-01-30 | 10X Genomics, Inc. | Systems and methods for metabolome analysis |
| US12163179B2 (en) | 2018-08-03 | 2024-12-10 | 10X Gemomics, Inc. | Methods and systems to minimize barcode exchange |
| WO2020041148A1 (fr) | 2018-08-20 | 2020-02-27 | 10X Genomics, Inc. | Procédés et systèmes pour la détection d'interactions protéine-adn à l'aide d'une ligature de proximité |
| US12065688B2 (en) | 2018-08-20 | 2024-08-20 | 10X Genomics, Inc. | Compositions and methods for cellular processing |
| CA3111887A1 (fr) | 2018-09-27 | 2020-04-02 | Grail, Inc. | Marqueurs de methylation et panels de sondes de methylation ciblees |
| CA3118990A1 (fr) * | 2018-11-21 | 2020-05-28 | Karius, Inc. | Procedes, systemes et compositions de bibliotheque directe |
| US11459607B1 (en) | 2018-12-10 | 2022-10-04 | 10X Genomics, Inc. | Systems and methods for processing-nucleic acid molecules from a single cell using sequential co-partitioning and composite barcodes |
| CN113286883A (zh) * | 2018-12-18 | 2021-08-20 | 格里尔公司 | 使用rna分析以检测疾病的方法 |
| US12390812B2 (en) | 2018-12-19 | 2025-08-19 | Nuclein, Llc | Apparatus and methods for molecular diagnostics |
| US12169198B2 (en) | 2019-01-08 | 2024-12-17 | 10X Genomics, Inc. | Systems and methods for sample analysis |
| US11845983B1 (en) | 2019-01-09 | 2023-12-19 | 10X Genomics, Inc. | Methods and systems for multiplexing of droplet based assays |
| WO2020167866A1 (fr) | 2019-02-12 | 2020-08-20 | 10X Genomics, Inc. | Systèmes et procédés pour le chargement de transposons |
| US11467153B2 (en) | 2019-02-12 | 2022-10-11 | 10X Genomics, Inc. | Methods for processing nucleic acid molecules |
| EP4674961A2 (fr) | 2019-02-12 | 2026-01-07 | 10X Genomics, Inc. | Procédés de traitement de molécules d'acides nucléiques |
| WO2020167862A1 (fr) | 2019-02-12 | 2020-08-20 | 10X Genomics, Inc. | Systèmes et procédés pour le transfert de réactifs entre des gouttelettes |
| US12305239B2 (en) | 2019-02-12 | 2025-05-20 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
| US11851683B1 (en) | 2019-02-12 | 2023-12-26 | 10X Genomics, Inc. | Methods and systems for selective analysis of cellular samples |
| US12275993B2 (en) | 2019-02-12 | 2025-04-15 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
| US11655499B1 (en) | 2019-02-25 | 2023-05-23 | 10X Genomics, Inc. | Detection of sequence elements in nucleic acid molecules |
| EP3938537A1 (fr) | 2019-03-11 | 2022-01-19 | 10X Genomics, Inc. | Systèmes et procédés de traitement de billes marquées optiquement |
| US11931674B2 (en) * | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| WO2020214547A1 (fr) * | 2019-04-15 | 2020-10-22 | Natera, Inc. | Biopsie liquide améliorée utilisant une sélection de taille |
| EP3980559A1 (fr) | 2019-06-06 | 2022-04-13 | Natera, Inc. | Procédés de détection d'adn de cellules immunitaires et de surveillance du système immunitaire |
| CN110468180A (zh) * | 2019-08-29 | 2019-11-19 | 北京优迅医学检验实验室有限公司 | 血浆dna文库及其构建方法 |
| US12235262B1 (en) | 2019-09-09 | 2025-02-25 | 10X Genomics, Inc. | Methods and systems for single cell protein analysis |
| WO2021139716A1 (fr) * | 2020-01-08 | 2021-07-15 | The Chinese University Of Hong Kong | Types de fragments d'adn biterminal dans des échantillons acellulaires et leurs utilisations |
| US12449419B1 (en) | 2020-02-12 | 2025-10-21 | 10X Genomics, Inc. | Methods for detecting binding of peptide-MHC monomers to T cells |
| US11475981B2 (en) | 2020-02-18 | 2022-10-18 | Tempus Labs, Inc. | Methods and systems for dynamic variant thresholding in a liquid biopsy assay |
| US11211144B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Methods and systems for refining copy number variation in a liquid biopsy assay |
| US11211147B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing |
| US11851700B1 (en) | 2020-05-13 | 2023-12-26 | 10X Genomics, Inc. | Methods, kits, and compositions for processing extracellular molecules |
| US12084715B1 (en) | 2020-11-05 | 2024-09-10 | 10X Genomics, Inc. | Methods and systems for reducing artifactual antisense products |
| US12480158B1 (en) | 2020-11-05 | 2025-11-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US12398262B1 (en) | 2021-01-22 | 2025-08-26 | 10X Genomics, Inc. | Triblock copolymer-based cell stabilization and fixation system and methods of use thereof |
| CN117015617B (zh) | 2021-02-23 | 2025-04-04 | 10X基因组学有限公司 | 基于探针的核酸和蛋白质分析 |
| US12297508B2 (en) * | 2021-10-05 | 2025-05-13 | Personalis, Inc. | Customized assays for personalized cancer monitoring |
| CN113913333B (zh) * | 2021-10-20 | 2022-09-02 | 南京世和基因生物技术股份有限公司 | 一种肺癌诊断标志物及用途 |
| JP2025527733A (ja) * | 2022-08-22 | 2025-08-22 | クーパーサージカル・インコーポレイテッド | Ｄｎａおよび無細胞ｄｎａの簡易解析法ならびにその使用 |
| US20240296920A1 (en) * | 2023-03-02 | 2024-09-05 | Grail, Llc | Redacting cell-free dna from test samples for classification by a mixture model |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477220B1 (fr) * | 1989-05-22 | 1996-09-04 | F. Hoffmann-La Roche Ag | Procedes d'etiquettage et d'indication de matieres a l'aide d'acides nucleiques |
| US6673621B1 (en) * | 1996-10-04 | 2004-01-06 | Intronn Llc | Sample collection devices and methods using markers and the use of such markers as controls in sample validation, laboratory evaluation and/or accreditation |
| US20080138798A1 (en) * | 2003-12-23 | 2008-06-12 | Greg Hampikian | Reference markers for biological samples |
| AU2006251937A1 (en) * | 2005-05-27 | 2006-11-30 | John Wayne Cancer Institute | Use of free circulating DNA for diagnosis, prognosis, and treatment of cancer |
| CA2668818C (fr) | 2006-10-10 | 2018-06-26 | Xenomics, Inc. | Compositions, procedes et trousses pour isoler acides nucleiques a partir de fluides corporels au moyen d'un milieu d'echange anionique |
| US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
| MX2010003724A (es) | 2007-10-04 | 2010-09-14 | Halcyon Molecular | Secuenciacion de polimeros de acido nucleico con microscopia electronica. |
| WO2009135205A2 (fr) | 2008-05-02 | 2009-11-05 | Advanced Liquid Logic, Inc. | Techniques d'actionneur de gouttelette utilisant des échantillons pouvant coaguler |
| WO2010002938A2 (fr) * | 2008-06-30 | 2010-01-07 | Life Technologies Corporation | Procédé d'amplification directe à partir d'échantillons bruts d'acides nucléiques |
| SI2334812T1 (sl) * | 2008-09-20 | 2017-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Building 170 | Neinvazivna diagnoza fetalne anevploidije s sekvenciranjem |
| US9080211B2 (en) | 2008-10-24 | 2015-07-14 | Epicentre Technologies Corporation | Transposon end compositions and methods for modifying nucleic acids |
| US11634747B2 (en) | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| EP3290530B1 (fr) | 2009-02-18 | 2020-09-02 | Streck Inc. | Préservation d'acides nucléiques acellulaires |
| WO2010129787A2 (fr) * | 2009-05-08 | 2010-11-11 | The Johns Hopkins University | Spectroscopie de molécule unique pour l'analyse de biomarqueurs d'acides nucléiques circulants |
| CA2690651C (fr) * | 2009-07-22 | 2016-10-04 | Streck, Inc. | Preservation des acides nucleiques foetaux dans le plasma maternel |
| US9260745B2 (en) * | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| US20120270739A1 (en) | 2010-01-19 | 2012-10-25 | Verinata Health, Inc. | Method for sample analysis of aneuploidies in maternal samples |
| ES2704701T3 (es) * | 2010-01-19 | 2019-03-19 | Verinata Health Inc | Nuevo protocolo de preparación de bibliotecas de secuenciación |
| US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
| EP2539450B1 (fr) | 2010-02-25 | 2016-02-17 | Advanced Liquid Logic, Inc. | Procédé de fabrication de banques d'acide nucléique |
| US8603742B2 (en) * | 2010-07-06 | 2013-12-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods for the diagnosis of fetal disease |
| PL2814981T3 (pl) * | 2012-02-13 | 2017-12-29 | Streck, Inc. | Urządzenie do pobierania krwi do stabilizacji pozakomórkowego dna w osoczu |
| US20150154352A1 (en) * | 2012-06-21 | 2015-06-04 | Gigagen, Inc. | System and Methods for Genetic Analysis of Mixed Cell Populations |
| CA2878246C (fr) | 2012-07-20 | 2022-01-11 | Verinata Health, Inc. | Detection et classification de variation du nombre de copies dans un genome de cancer |
| EP3409791B1 (fr) | 2013-03-15 | 2021-06-30 | Verinata Health, Inc. | Génération de banques d'adn acellulaire provenant directement du sang |
-
2014
- 2014-03-14 EP EP18184795.5A patent/EP3409791B1/fr active Active
- 2014-03-14 WO PCT/US2014/029739 patent/WO2014145078A1/fr not_active Ceased
- 2014-03-14 AU AU2014233373A patent/AU2014233373B2/en not_active Ceased
- 2014-03-14 EP EP14717959.2A patent/EP2971097B1/fr not_active Not-in-force
- 2014-03-14 CA CA3156663A patent/CA3156663A1/fr active Pending
- 2014-03-14 CA CA2906818A patent/CA2906818C/fr active Active
- 2014-03-14 US US14/214,277 patent/US10017807B2/en active Active
-
2018
- 2018-06-11 US US16/005,502 patent/US10400267B2/en active Active
-
2019
- 2019-07-17 US US16/514,748 patent/US20190338345A1/en not_active Abandoned
-
2020
- 2020-01-21 AU AU2020200418A patent/AU2020200418B2/en not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111742058A (zh) * | 2018-02-21 | 2020-10-02 | 纽克莱克斯有限公司 | 用于确定从全血分离血浆的效率的方法和试剂盒 |
| US12378602B2 (en) | 2018-02-21 | 2025-08-05 | Nucleix Ltd. | Methods and kits for determining the efficiency of plasma separation from whole blood |
Also Published As
| Publication number | Publication date |
|---|---|
| US10400267B2 (en) | 2019-09-03 |
| US20190338345A1 (en) | 2019-11-07 |
| AU2020200418A1 (en) | 2020-02-13 |
| AU2014233373B2 (en) | 2019-10-24 |
| HK1218936A1 (en) | 2017-03-17 |
| CA3156663A1 (fr) | 2014-09-18 |
| EP2971097A1 (fr) | 2016-01-20 |
| EP2971097B1 (fr) | 2018-08-01 |
| CA2906818C (fr) | 2022-08-16 |
| AU2020200418B2 (en) | 2021-09-23 |
| US10017807B2 (en) | 2018-07-10 |
| US20180346967A1 (en) | 2018-12-06 |
| EP3409791B1 (fr) | 2021-06-30 |
| AU2014233373A1 (en) | 2015-10-01 |
| WO2014145078A1 (fr) | 2014-09-18 |
| EP3409791A1 (fr) | 2018-12-05 |
| US20140274740A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020200418B2 (en) | Generating cell-free DNA libraries directly from blood | |
| US20230340590A1 (en) | Method for verifying bioassay samples | |
| EP3656875B1 (fr) | Diagnostic prénatal non invasif | |
| HK40001534A (en) | Generating cell-free dna libraries directly from blood | |
| HK40001534B (en) | Generating cell-free dna libraries directly from blood | |
| HK1218936B (en) | Generating cell-free dna libraries directly from blood | |
| US20260002195A1 (en) | Method for analyzing blood stored for later analysis of cell free dna | |
| HK40067006A (en) | Non-invasive prenatal diagnosis of fetal genetic conditions using cellular dna and cell free dna | |
| HK40030598A (en) | Non-invasive prenatal diagnosis | |
| HK40030598B (en) | Non-invasive prenatal diagnosis | |
| HK1193847B (en) | Method for verifying bioassay samples | |
| HK1193847A (en) | Method for verifying bioassay samples | |
| HK1238299B (en) | Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna | |
| HK1238299A1 (en) | Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna | |
| HK1260078A1 (en) | Deep sequencing profiling of tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190304 |
|
| EEER | Examination request |
Effective date: 20190304 |
|
| EEER | Examination request |
Effective date: 20190304 |